Lisata Therapeutics Inc. (LSTA)
| Bid | 2.36 |
| Market Cap | 20.98M |
| Revenue (ttm) | 1M |
| Net Income (ttm) | -19.31M |
| EPS (ttm) | -2.3 |
| PE Ratio (ttm) | -1.06 |
| Forward PE | -2.65 |
| Analyst | Buy |
| Ask | 2.69 |
| Volume | 14,102 |
| Avg. Volume (20D) | 12,517 |
| Open | 2.57 |
| Previous Close | 2.48 |
| Day's Range | 2.44 - 2.57 |
| 52-Week Range | 1.87 - 4.20 |
| Beta | 1.00 |
About LSTA
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for LSTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 week ago · proactiveinvestors.com
Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC HealthLisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate of drug development using artificial intelligence (AI)...
1 month ago · proactiveinvestors.com
Lisata eyes key trial milestones in 2025 as certepetide development gains momentumLisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it expects a data-rich year ahead as it advances multiple trials of its lead asset, certepetide, a novel peptide-based therapy being tested in a ...
2 months ago · proactiveinvestors.com
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMILisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors tha...
